INmune Bio Inc. - Common stock (INMB) Social Stream



INmune Bio Inc. - Common stock (INMB): $8.61

0.18 (+2.14%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add INMB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#329 of 363

in industry

INMUNE BIO INC (INMB) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering INMUNE BIO INC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 2 $42 $32 $37 $13.04 183.74%
2022-01-24 2 $42 $20 $31 $13.04 137.73%
2022-03-07 2 $42 $14 $28 $13.04 114.72%
2022-05-11 2 $22 $14 $18 $13.04 38.04%
2022-05-24 3 $22 $7 $14.333 $13.04 9.92%
2022-12-16 2 $22 $7 $14.333 $13.04 9.92%
2023-06-01 2 $16 $16 $16 $13.04 22.7%
2023-10-20 2 $22.001 $16 $19 $13.04 45.71%
NA 1 $NA $NA $NA $13.04 NA%

The Trend in the Analyst Price Target


INMB's average price target has moved down $13.75 over the prior 25 months.

Over the past 141 days, INMB's average upside potential has been 133.71%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-06-01 2 16.000 16 16 7.840 104.08%
2023-06-01 1 16.000 16 16 7.840 104.08%
2023-10-20 2 22.001 16 19 7.215 163.34%
2023-10-20 3 22.001 16 19 7.215 163.34%

INMB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 2 0 0 0 0 2

The Trend in the Broker Recommendations


INMB's average broker recommendation rating improved by 1 over the prior 14 months.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for INMB as an investment opportunity.

  • In terms of how INMUNE BIO INC fares relative to all US stocks, note that its number of analysts covering the stock is higher than 41.95% of that group.
  • INMB has a lower variance in analysts' estimates than -534.28% of all US stocks.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, INMUNE BIO INC's upside potential (average analyst target price relative to current price) is higher than 419.95% of them.
  • INMUNE BIO INC's average analyst price target is greater than 434.6% of Healthcare stocks.

Stocks similar to INMUNE BIO INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are GMDA, GRTS, and AUTL.

Is INMB a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!